Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies

Annals of Oncology

Volumn 28, Issue 11, 2017, Pages 2860-2865

  Collins, M ^a,b   M Michot, J ^c   X Danlos, F ^c   Mussini, C ^a,b   Soularue, E ^a,b   Mateus, C ^c   Loirat, D ^d   Buisson, A ^e   Rosa, I ^f   Lambotte, O ^a,b,g,h   Laghouati, S ^c   Chaput, N ^b,i   Coutzac, C ^b,i   Voisin, A L ^c   Soria, J C ^c   Marabelle, A ^c   Champiat, S ^c   Robert, C ^c   Carbonnel, F ^a,b  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Curie Research Institute   (France)

^e UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^f CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^g DIF   (France)

^h INSERM   (France)

ⁱ CNRS UMS3655   (France)

Author keywords

Anti PD 1; Auto immune gastritis; Immune check point blockade; Immune related adverse event; Microscopic colitis

Indexed keywords

CORTICOSTEROID; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; INTESTINE OBSTRUCTION; INTESTINE PSEUDOOBSTRUCTION; MALE; MALIGNANT NEOPLASM; MICROSCOPIC COLITIS; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; UPPER GASTROINTESTINAL TRACT; ANTAGONISTS AND INHIBITORS; FOLLOW UP; GASTROINTESTINAL DISEASE; IMMUNOLOGY; INFLAMMATION; MIDDLE AGED; NEOPLASM; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 85033775788     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx403     Document Type: Article

References (24)

1. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723
2. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133
3. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526
4. Marthey L, Mateus C, Mussini C et al. Cancer Immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 2016; jjv227. doi:10.1093/ecco-jcc/jjv227
5. Gupta A, De Felice KM, Loftus EV et al. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 2015; 42: 406-417
6. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330
7. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34
8. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375-384
9. Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-2017
10. Ansell SM, Lesokhin AM, Borello I et al. PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-319
11. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135
12. Motzer RJ, Escudier B,McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl JMed 2015; 373: 1803-1813
13. Ferris RL, Blumenschein G, Fayette J et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; doi: 10.1056/NEJMoa1602252
14. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-2520
15. Champiat S, Lambotte O, Barreau E et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27: 559-574
16. Baroudjian B, Lourenco N, Pages C et al. Anti-PD1-induced collagenous colitis in a melanoma patient. Melanoma Res 2016; 26: 308-311
17. Gonzalez RS, Salaria SN, Bohannon CD et al. PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'. Histopathology 2016; doi:10.1111/his.13118
18. Johnson DB, Balko JM, Compton ML et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016; 375: 1749-1755
19. Boutros C, Tarhini A, Routier E et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016; doi:10.1038/nrclinonc.2016.58
20. Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance: the role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci 2011; 1217: 45-59
21. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236: 219-242
22. Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 2016; 375: 1767-1778
23. Abdel-Rahman O. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. Crit Rev Oncol Hematol 2016; 101: 75-85
24. Barnes MJ, Griseri T, Johnson AMF et al. CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria. Mucosal Immunol 2013; 6: 324-334